Announcements Trials
Browse Landscape

Status

No longer available 1Approved for marketing 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 28Expanded_access 2Observational 1

Sponsor

Cancer Type

Plasma cell 2

Conditions

Recurrence 2Multiple Myeloma 2

Interventions

3-Iodobenzylguanidine 2Gemcitabine 2Powders 2Suspensions 2balstilimab 2leronlimab 2ruxolitinib 2talquetamab 2Abiraterone Acetate 1Alpelisib 1Androgen Antagonists 1Asparaginase 1Bone Marrow Transplantation 1Capecitabine 1Cyclophosphamide 1Docetaxel 1Eflornithine 1FANG vaccine 1HMPL-013 1Hydrocortisone 1Immunotherapy, Adoptive 1Insulin Infusion Systems 1LY3023414 1Magnetic Resonance Spectroscopy 1Methionine 1Nivolumab 1Paclitaxel 1Peripheral Blood Stem Cell Transplantation 1Prednisolone 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × talquetamab × 1 year × Clear all
NCT05503550 2025-12-16

Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

Janssen Research & Development, LLC

No longer available
Plasma cell

Multiple Myeloma, Recurrence

NCT05757973 2025-12-09

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Janssen Research & Development, LLC

Approved for marketing
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡